A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Relapsing Multiple Sclerosis (RMS)
Condition(s) studied
Investigational drug(s) / intervention(s)
Ocrelizumab: The actual higher dose of ocrelizumab will be assigned to participants based on their body weight at baseline: 1200 mg (body weight \<75 kg) or 1800 mg (body weight ≥ 75 kg). The first dose of ocrelizumab will be administered as two 600 mg or 900 mg IV infusions given 14 days apart. For the subsequent doses, ocrelizumab will be administered as a single 1200 mg or 1800 mg IV infusion Q24W. During the optional OLE phase, participants will continue with their assigned dose of ocrelizumab (either 1200 or 1800 mg) for approximately 96 weeks (4 doses in total).
Ocrelizumab: Ocrelizumab will be administered at a dose of 600 mg Q24W. The first dose of ocrelizumab will be administered as two 300 mg IV infusions given 14 days apart. For the subsequent doses, ocrelizumab will be administered as a single 600 mg IV infusion Q24W.
Antihistamine: Premedication with oral or IV antihistaminic drug (i.e., diphenhydramine 50 mg or an equivalent dose of an alternative) will be administered prior to each ocrelizumab infusion.
Methylprednisolone: Premedication with 100 mg of methylprednisolone (or equivalent) will be administered by IV infusion prior to each ocrelizumab infusion.
Study summary
This is a randomized, double-blind, controlled, parallel group, multicenter study to evaluate efficacy, safety and PK of a higher dose of ocrelizumab per intravenous (IV) infusion every 24 weeks (Q24W) in participants with RMS, in comparison to the approved 600 milligrams (mg) dose of ocrelizumab.
Eligibility
Primary outcome measure(s)
- Time to Onset of 12-week Composite Confirmed Disability Progression (cCDP12) — Up to approximately 4 years
Time to onset of 12-week cCDP=first occurrence of a 12-week cCDP according to at least 1 of the 3 criteria: 1) CDP=12-week confirmed increase (CI) from baseline (FB) in expanded disability status scale (EDSS) score of ≥1.0 point in participants with baseline EDSS score of ≤5.5 or 12-week CI≥0.5 point in participants with baseline EDSS score of \>5.5 OR 2) 12-week CI of ≥20% FB in Timed 25-foot Walk Test (T25FWT) score OR 3)12-week CI of ≥ 20% FB in 9-hole Peg Test (9-HPT) score. EDSS = disability scale that ranges in 0.5-point steps from 0 \[normal\]-10.0 \[death\]. In T25FWT test participants walked to a 25 foot course as quickly \& safely as possible. Score = average of 2 completed trials (in seconds). In 9-HPT, participants had to place \& remove pegs 1 by 1 into 9 holes arranged in a board \& complete 2 successful trials for each hand \& the amount of time (in seconds) required was recorded. In T25FWT \& 9-HPT the longer it took complete test= higher scores, indicating deterioration.
Trial sites (121)
| Facility | City | Region | Status |
|---|---|---|---|
| North Central Neurology Associates | Cullman | Alabama | |
| Alabama Neurology Associates | Homewood | Alabama | |
| 21st Century Neurology | Phoenix | Arizona | |
| Profound Research, LLC | Carlsbad | California | |
| Stanford University Medical Center | Stanford | California | |
| Advanced Neurology of Colorado, LLC | Fort Collins | Colorado | |
| Neurology Associates, PA | Maitland | Florida | |
| University of South Florida | Tampa | Florida | |
| American Health Network Institute, LLC | Avon | Indiana | |
| University of Kansas Medical Center | Kansas City | Kansas | |
| The NeuroMedical Clinic of Central Louisiana | Alexandria | Louisiana | |
| Maine Medical Center | Scarborough | Maine | |
| Dragonfly Research, LLC | Wellesley | Massachusetts | |
| Henry Ford Health System | Detroit | Michigan | |
| Washington University School of Medicine | St Louis | Missouri | |
| Cleveland Clinic Lou Ruvo | Las Vegas | Nevada | |
| Dent Neurological Institute | Amherst | New York | |
| UC Health Neurology | Dayton | Ohio | |
| Oklahoma Medical Research Foundation | Oklahoma City | Oklahoma | |
| Abington Neurological Associates | Willow Grove | Pennsylvania | |
| Tri-State Mountain Neurology | Johnson City | Tennessee | |
| Hope Neurology | Knoxville | Tennessee | |
| Bhupesh Dihenia M.D. P.A. | Lubbock | Texas | |
| Lone Star Neurology of San Antonio | San Antonio | Texas | |
| Evergreen MS Center | Kirkland | Washington | |
| Centro de Especialidades Neurológicas y Rehabilitación - CENyR | Buenos Aires | Argentina | |
| CEMIC | Buenos Aires | Argentina | |
| Centro de Investigaciones Médicas Tucuman | San Miguel de Tucumán | Argentina | |
| Austin Hospital | Heidelberg | Victoria | |
| Hospital Erasme | Brussels | Belgium | |
| Revalidatie en MS Centrum | Overpelt | Belgium | |
| Instituto de Neurologia de Curitiba | Curitiba | Paraná | |
| IMV Pesquisa Neurológica | Porto Alegre | Rio Grande do Sul | |
| Clinica Neurologica | Joinville | Santa Catarina | |
| CPQuali Pesquisa Clinica Ltda | São Paulo | São Paulo | |
| Recherche Sepmus Inc. | Greenfield Park | Quebec | |
| Centre de Recherche Saint-Louis | Lévis | Quebec | |
| Rigshospitalet Glostrup | Glostrup Municipality | Denmark | |
| Groupe Hospitalier Pellegrin | Bordeaux | France | |
| CHU Hopital Gabriel Montpied | Clermont-Ferrand | France |
+ 81 more sites — see the full list on the official registry below.
On this site
📄 Ocrevus (ocrelizumab) drug profile →More Hoffmann-La Roche trials in Italy
Other trials for the same condition
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT04544436 on ClinicalTrials.gov ↗ ← All trials in Italy